Display options
Cite
Lopez-Cantu DO, Wang X, Carrasco-Magallanes H, et al. From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nanomicro Lett. 2022;14(1):41doi: 10.1007/s40820-021-00771-8.
Lopez-Cantu, D. O., Wang, X., Carrasco-Magallanes, H., Afewerki, S., Zhang, X., Bonventre, J. V., & Ruiz-Esparza, G. U. (2022). From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nano-micro letters, 14(1), 41. https://doi.org/10.1007/s40820-021-00771-8
Lopez-Cantu, Diana O, et al. "From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines." Nano-micro letters vol. 14,1 (2022): 41. doi: https://doi.org/10.1007/s40820-021-00771-8
Lopez-Cantu DO, Wang X, Carrasco-Magallanes H, Afewerki S, Zhang X, Bonventre JV, Ruiz-Esparza GU. From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nanomicro Lett. 2022 Jan 03;14(1):41. doi: 10.1007/s40820-021-00771-8. PMID: 34981278; PMCID: PMC8722410.
Copy Download .nbib Format: NLM
Share it on

Nanomicro Lett. 2022 Jan 03;14(1):41. doi: 10.1007/s40820-021-00771-8.

From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines.

Nano-micro letters

Diana O Lopez-Cantu, Xichi Wang, Hector Carrasco-Magallanes, Samson Afewerki, Xingcai Zhang, Joseph V Bonventre, Guillermo U Ruiz-Esparza

Affiliations

  1. Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  2. Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Boston, MA, 02115, USA.
  3. Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
  4. Tecnologico de Monterrey, School of Engineering and Sciences, 64849, Monterrey, NL, Mexico.
  5. Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
  6. Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.
  7. Tecnologico de Monterrey, School of Medicine and Health Sciences, 64849, Monterrey, NL, Mexico.
  8. John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA, 02138, USA. [email protected].
  9. School of Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. [email protected].
  10. Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. [email protected].
  11. Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Boston, MA, 02115, USA. [email protected].
  12. Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. [email protected].
  13. Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. [email protected].
  14. Division of Health Sciences and Technology, Harvard University - Massachusetts Institute of Technology, Boston, MA, 02115, USA. [email protected].
  15. Division of Renal Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA. [email protected].

PMID: 34981278 PMCID: PMC8722410 DOI: 10.1007/s40820-021-00771-8

Abstract

During the last decades, the use of nanotechnology in medicine has effectively been translated to the design of drug delivery systems, nanostructured tissues, diagnostic platforms, and novel nanomaterials against several human diseases and infectious pathogens. Nanotechnology-enabled vaccines have been positioned as solutions to mitigate the pandemic outbreak caused by the novel pathogen severe acute respiratory syndrome coronavirus 2. To fast-track the development of vaccines, unprecedented industrial and academic collaborations emerged around the world, resulting in the clinical translation of effective vaccines in less than one year. In this article, we provide an overview of the path to translation from the bench to the clinic of nanotechnology-enabled messenger ribonucleic acid vaccines and examine in detail the types of delivery systems used, their mechanisms of action, obtained results during each phase of their clinical development and their regulatory approval process. We also analyze how nanotechnology is impacting global health and economy during the COVID-19 pandemic and beyond.

© 2021. The Author(s).

Keywords: COVID-19; Coronavirus; Nanovaccines; SARS-CoV-2;  mRNA

References

  1. ACS Nano. 2021 Jun 28;: - PubMed
  2. N Engl J Med. 2021 Sep 30;385(14):1332-1334 - PubMed
  3. Nanomedicine. 2012 Nov;8(8):1337-44 - PubMed
  4. J Virol. 2007 Mar;81(5):2249-62 - PubMed
  5. J Virol. 2004 Jun;78(11):5642-50 - PubMed
  6. Cell Res. 2020 Oct;30(10):936-939 - PubMed
  7. Vaccines (Basel). 2019 Sep 20;7(4): - PubMed
  8. Nat Nanotechnol. 2021 Apr;16(4):1-14 - PubMed
  9. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt A):427-43 - PubMed
  10. Nat Rev Drug Discov. 2021 Feb;20(2):101-124 - PubMed
  11. Curr Probl Cardiol. 2020 Aug;45(8):100618 - PubMed
  12. J Virol. 2014 Jan;88(2):1293-307 - PubMed
  13. Cell Death Differ. 2021 Feb;28(2):626-639 - PubMed
  14. Small Methods. 2021 Sep;5(9):e2100402 - PubMed
  15. Pharm Res. 2016 Oct;33(10):2373-87 - PubMed
  16. Nat Rev Genet. 2008 Oct;9(10):776-88 - PubMed
  17. N Engl J Med. 2020 Oct 15;383(16):1544-1555 - PubMed
  18. Proc Am Philos Soc. 2006 Mar;150(1):86-112 - PubMed
  19. Molecules. 2017 Aug 23;22(9): - PubMed
  20. Nano Today. 2019 Aug;27:73-98 - PubMed
  21. Front Pharmacol. 2015 Dec 01;6:286 - PubMed
  22. Nat Biotechnol. 2015 Sep;33(9):941-51 - PubMed
  23. Nanotheranostics. 2017 Jun 9;1(3):244-260 - PubMed
  24. Nat Rev Microbiol. 2021 Jul;19(7):409-424 - PubMed
  25. Eur J Intern Med. 2021 Oct;92:28-30 - PubMed
  26. N Engl J Med. 2021 Jul 8;385(2):187-189 - PubMed
  27. Mol Pharm. 2008 Jul-Aug;5(4):505-15 - PubMed
  28. J Nanobiotechnology. 2018 Sep 19;16(1):71 - PubMed
  29. Nat Med. 2021 Apr;27(4):622-625 - PubMed
  30. Nature. 2020 Oct;586(7830):567-571 - PubMed
  31. N Engl J Med. 2020 Nov 12;383(20):1920-1931 - PubMed
  32. Nat Hum Behav. 2020 Jul;4(7):677-687 - PubMed
  33. Nat Microbiol. 2020 Oct;5(10):1185-1191 - PubMed
  34. Nano Today. 2021 Feb;36:101019 - PubMed
  35. Nat Med. 2020 Apr;26(4):450-452 - PubMed
  36. Cell. 2017 Mar 9;168(6):1114-1125.e10 - PubMed
  37. Nat Rev Gastroenterol Hepatol. 2020 Aug;17(8):441-443 - PubMed
  38. MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1922-1924 - PubMed
  39. Cell Rep Med. 2021 Jul 20;2(7):100355 - PubMed
  40. Adv Mater. 2013 Nov 6;25(41):5928-36 - PubMed
  41. Avicenna J Med Biotechnol. 2009 Jul;1(2):71-88 - PubMed
  42. Nat Rev Drug Discov. 2005 Jul;4(7):581-93 - PubMed
  43. Sci Immunol. 2020 May 13;5(47): - PubMed
  44. Adv Healthc Mater. 2014 Aug;3(8):1194-9 - PubMed
  45. Nature. 2016 Jun 01;534(7607):396-401 - PubMed
  46. PLoS One. 2019 Jun 4;14(6):e0215031 - PubMed
  47. Gene Ther. 2000 Jan;7(2):89-92 - PubMed
  48. Nat Protoc. 2021 Jan;16(1):327-351 - PubMed
  49. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011 Mar-Apr;3(2):174-196 - PubMed
  50. Virol J. 2019 May 27;16(1):69 - PubMed
  51. Nat Med. 2021 Nov;27(11):2002-2011 - PubMed
  52. Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6 - PubMed
  53. Nat Nanotechnol. 2020 May;15(5):406-416 - PubMed
  54. JAMA. 1967 Dec 18;202(12):1075-80 - PubMed
  55. Allergy. 2022 Jan;77(1):243-257 - PubMed
  56. Expert Opin Drug Deliv. 2007 May;4(3):197-213 - PubMed
  57. Sci Rep. 2016 May 12;6:25720 - PubMed
  58. NPJ Vaccines. 2021 Feb 22;6(1):28 - PubMed
  59. NPJ Vaccines. 2021 Apr 22;6(1):63 - PubMed
  60. J Virol. 2005 Dec;79(23):14614-21 - PubMed
  61. Viruses. 2019 Dec 28;12(1): - PubMed
  62. Nat Rev Immunol. 2021 May;21(5):274 - PubMed
  63. Science. 1990 Mar 23;247(4949 Pt 1):1465-8 - PubMed
  64. Front Pharmacol. 2014 Apr 25;5:77 - PubMed
  65. Nature. 2020 Oct;586(7830):589-593 - PubMed
  66. J Zhejiang Univ Sci B. 2007 Mar;8(3):153-61 - PubMed
  67. Nano Today. 2019 Apr;25:85-98 - PubMed
  68. Eur Respir J. 2020 Apr 16;55(4): - PubMed
  69. Nat Rev Immunol. 2013 Aug;13(8):592-605 - PubMed
  70. Nano Today. 2015 Aug;10(4):487-510 - PubMed
  71. Nat Commun. 2012;3:1303 - PubMed
  72. Nanomedicine. 2009 Dec;5(4):463-72 - PubMed
  73. J Pathol. 2004 Jun;203(2):631-7 - PubMed
  74. ACS Nano. 2015 Jul 28;9(7):6918-33 - PubMed
  75. Pediatr Res. 2021 Dec;90(6):1102-1103 - PubMed
  76. J Control Release. 2011 Jan 5;149(1):65-71 - PubMed
  77. Sci Rep. 2020 Dec 8;10(1):21446 - PubMed
  78. Lancet. 2021 Feb 6;397(10273):452-455 - PubMed
  79. Cell. 2021 Sep 16;184(19):4848-4856 - PubMed
  80. J Postgrad Med. 2016 Jan-Mar;62(1):4-11 - PubMed
  81. N Engl J Med. 2021 Feb 4;384(5):403-416 - PubMed
  82. Int J Mol Sci. 2018 Nov 15;19(11): - PubMed
  83. Nature. 2021 Apr;592(7855):616-622 - PubMed
  84. Cell. 2021 Apr 29;184(9):2348-2361.e6 - PubMed
  85. J Infect Dis. 2021 May 28;223(10):1666-1670 - PubMed
  86. Clin Exp Vaccine Res. 2015 Jan;4(1):46-53 - PubMed
  87. Nature. 2021 Aug;596(7871):276-280 - PubMed
  88. Vaccines (Basel). 2020 Mar 20;8(1): - PubMed
  89. Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):129-137 - PubMed
  90. Respir Res. 2005 Jan 20;6:8 - PubMed
  91. Nat Nanotechnol. 2020 Aug;15(8):646-655 - PubMed
  92. J Autoimmun. 2020 May;109:102433 - PubMed
  93. Pediatrics. 2021 Sep;148(3): - PubMed
  94. Vaccines (Basel). 2019 Sep 27;7(4): - PubMed
  95. Circulation. 2021 Aug 10;144(6):471-484 - PubMed
  96. Nat Rev Drug Discov. 2018 Apr;17(4):261-279 - PubMed
  97. Mol Cell Biol Hum Dis Ser. 1995;5:64-82 - PubMed
  98. Lancet. 2020 Sep 12;396(10253):741-743 - PubMed
  99. N Engl J Med. 2020 Dec 17;383(25):2427-2438 - PubMed
  100. Nat Rev Mater. 2021 Aug 10;:1-17 - PubMed
  101. Vaccine. 2007 Jul 26;25(30):5563-76 - PubMed
  102. Nat Biotechnol. 2020 May;38(5):523-532 - PubMed
  103. Mol Ther. 2021 Mar 3;29(3):898-900 - PubMed
  104. Mol Ther. 2017 Jun 7;25(6):1316-1327 - PubMed
  105. Vaccine. 2012 Mar 16;30(13):2256-72 - PubMed
  106. Am J Epidemiol. 1969 Apr;89(4):422-34 - PubMed
  107. Expert Rev Vaccines. 2017 Sep;16(9):871-881 - PubMed
  108. Nat Rev Immunol. 2010 Oct;10(10):699-711 - PubMed
  109. Acta Biomater. 2019 Aug;94:44-63 - PubMed
  110. Cancer Immunol Immunother. 2007 Aug;56(8):1251-64 - PubMed
  111. N Engl J Med. 2021 May 20;384(20):1899-1909 - PubMed
  112. Vaccine. 2007 Jan 2;25(1):144-53 - PubMed
  113. Biomater Res. 2019 Nov 21;23:20 - PubMed
  114. Bioeng Transl Med. 2019 Sep 05;4(3):e10143 - PubMed
  115. Nature. 2020 Apr;580(7805):578-580 - PubMed
  116. Front Immunol. 2018 Sep 19;9:1963 - PubMed
  117. Nature. 2021 Apr;592(7853):283-289 - PubMed
  118. Nat Med. 2020 Jul;26(7):1017-1032 - PubMed
  119. Vaccine. 2021 May 12;39(20):2791-2799 - PubMed
  120. Chem Soc Rev. 2018 Nov 26;47(23):8572-8610 - PubMed
  121. Respir Res. 2020 Jun 29;21(1):163 - PubMed
  122. J Nanobiotechnology. 2013 Sep 11;11:30 - PubMed
  123. Sci Transl Med. 2019 Dec 18;11(523): - PubMed
  124. Vaccine. 2015 Sep 22;33(39):5064-71 - PubMed
  125. Pharmaceutics. 2020 Jan 28;12(2): - PubMed
  126. Front Immunol. 2019 Mar 27;10:594 - PubMed
  127. Sci Rep. 2020 Jun 25;10(1):10365 - PubMed
  128. J Control Release. 2010 Jun 1;144(2):118-26 - PubMed
  129. Sci Rep. 2020 Mar 4;10(1):4017 - PubMed
  130. Methods Mol Biol. 2015;1282:1-23 - PubMed
  131. Cell. 2020 Apr 16;181(2):271-280.e8 - PubMed
  132. Adv Mater. 2018 May 7;:e1705328 - PubMed
  133. Molecules. 2018 Aug 31;23(9): - PubMed
  134. Nat Rev Immunol. 2020 Jun;20(6):363-374 - PubMed
  135. Nature. 2021 May;593(7857):136-141 - PubMed
  136. NPJ Vaccines. 2017 Sep 5;2:24 - PubMed
  137. J Mol Biol. 2004 Apr 2;337(4):905-15 - PubMed
  138. Eur J Pharm Biopharm. 2012 Feb;80(2):241-6 - PubMed
  139. Biostatistics. 2019 Apr 1;20(2):273-286 - PubMed
  140. Nat Rev Mater. 2020 Oct 14;:1-14 - PubMed
  141. N Engl J Med. 2020 Dec 31;383(27):2603-2615 - PubMed
  142. Nat Rev Cardiol. 2020 Sep;17(9):543-558 - PubMed
  143. Nature. 2021 May;593(7857):130-135 - PubMed
  144. Cell Rep. 2021 Feb 2;34(5):108699 - PubMed
  145. Exp Biol Med (Maywood). 2016 May;241(9):919-29 - PubMed
  146. Nat Biotechnol. 2012 Dec;30(12):1210-6 - PubMed
  147. MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):753-758 - PubMed
  148. Front Microbiol. 2020 Feb 28;11:298 - PubMed
  149. Heart Lung. 2020 Nov - Dec;49(6):883-884 - PubMed

Publication Types